- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05066763
Parkinson's Foundation Surveys
September 23, 2021 updated by: Parkinson's Foundation
Parkinson's Foundation Surveys is an initiative seeking to periodically survey people with Parkinson's disease (PD), their care partners and medical professionals to better understand specific aspects of living with PD.
Study Overview
Study Type
Observational
Enrollment (Anticipated)
1000000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33131
- Recruiting
- Parkinson's Foundation
-
Contact:
- Megan Feeney, MPH
- Phone Number: 646-388-7674
- Email: mfeeney@parkinson.org
-
Principal Investigator:
- James C Beck, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
People with Parkinson's disease, care partners of people with Parkinson's disease, health professional that treats people with Parkinson's disease
Description
Inclusion Criteria:
- Willingness to be contacted by the Parkinson's Foundation for surveys and any future research opportunities
- Anyone who self-reports that they have a diagnosis of Parkinson's disease
- Care partner of a person with Parkinson's disease
- Any health professional that regularly works with people with Parkinson's disease
- 18 years of age or older
Exclusion Criteria:
- People who report that they do not have a diagnosis of Parkinson's disease, are not a care partner to someone with PD or do not work with people with PD in the health setting
- An individual younger than 18 years of age
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
People with Parkinson's disease
|
non-interventional
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total number of survey respondents
Time Frame: 10 years
|
Total number of survey participants who consent into the study
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 2, 2021
Primary Completion (Anticipated)
December 1, 2030
Study Completion (Anticipated)
December 1, 2030
Study Registration Dates
First Submitted
September 23, 2021
First Submitted That Met QC Criteria
September 23, 2021
First Posted (Actual)
October 4, 2021
Study Record Updates
Last Update Posted (Actual)
October 4, 2021
Last Update Submitted That Met QC Criteria
September 23, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PF-Surveys-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
De-identified and coded survey responses may be shared with other researchers.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Non-interventional
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)RecruitingUse of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMCHIV Infections | Cancer | HPV-Related Malignancy | Anal Cancer | HIV-Associated Malignant Neoplasm | AIDS Related Lymphoma | AIDS-related Kaposi Sarcoma | AIDS-Related MalignancyUnited States
-
Bristol-Myers SquibbWithdrawnNon-valvular Atrial FibrillationUnited States
-
Papworth Hospital NHS Foundation TrustInnovate UK; Cystic Fibrosis Trust; US Cystic Fibrosis FoundationRecruitingCystic FibrosisUnited Kingdom
-
Royal Marsden NHS Foundation TrustRecruiting
-
Regeneron PharmaceuticalsRecruitingHemophilia BUnited States, Germany, United Kingdom, Canada
-
Henri Mondor University HospitalEuropean Society of Intensive Care MedicineRecruitingFournier Gangrene | Necrotizing Soft Tissue Infection | Necrotizing FasciitisFrance
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
Respiratory Effectiveness GroupBoehringer IngelheimCompletedChronic Obstructive Pulmonary DiseaseKorea, Republic of, Singapore, Malta, Italy, Slovenia, Spain
-
Eurasian Association of TherapistsCompletedCardiovascular Diseases | Pneumonia | Hypertension | Diabetes | Covid19 | Coronary Heart Disease | Copd | CKD | Overweight and Obesity | SARS-CoV-2 Infection | Cardiac EventRussian Federation